The US Food and Drug Administration (FDA) has accepted a resubmission of the supplemental Biologics License Application for ...
Dupilumab (Dupixent), a fully human monoclonal antibody that targets the interleukin (IL)-4 and IL-13 pathways, is currently ...
A new study published in the journal of Respiratory Medicine showed that patients with type 2 inflammation and chronic ...
Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...
GlobalData on MSN4d
FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticariaThe FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.
The following is a summary of “Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic ...
The resubmitted sBLA will include results from Study C, which evaluated biologic-naive patients with uncontrolled CSU on antihistamines.
GlobalData on MSN12d
EMA approves Sanofi/Regeneron’s Dupixent for young EoE patientsThe safety results from the EoE KIDS study were consistent with the known safety profile of Dupixent in adolescents and ...
Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.
Dupilumab in COPD was associated with decreased risk of mortality, emergency visits, exacerbations, and respiratory failure and infections.
The following is a summary of “Integrative epidemiology and immuno-transcriptomics uncover a risk and potential mechanism for ...
US FDA accepts for review the resubmission of sBLA for Dupixent to treat chronic spontaneous urticaria: Paris Monday, November 18, 2024, 11:00 Hrs [IST] The US Food and Drug Admin ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback